John G Ullman & Associates Inc. Has $711,000 Holdings in Becton, Dickinson and Company $BDX

Key Points

• John G Ullman & Associates Inc. reduced its holdings in Becton, Dickinson and Company by 85.9% in the second quarter, now owning only 4,125 shares worth approximately $711,000.
• Several hedge funds have acquired new stakes in Becton, Dickinson and Company, with 86.97% of the stock owned by institutional investors and hedge funds.
• Analysts maintain a consensus rating of "Hold" on Becton, Dickinson and Company, with a target price averaging $205.40.

John G Ullman & Associates Inc. cut its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 85.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,125 shares of the medical instruments supplier's stock after selling 25,233 shares during the period. John G Ullman & Associates Inc.'s holdings in Becton, Dickinson and Company were worth $711,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of BDX. Saudi Central Bank acquired a new stake in Becton, Dickinson and Company during the first quarter worth approximately $26,000. Smallwood Wealth Investment Management LLC acquired a new stake in Becton, Dickinson and Company during the first quarter worth approximately $27,000. Alpine Bank Wealth Management bought a new position in shares of Becton, Dickinson and Company during the first quarter worth approximately $29,000. Cornerstone Planning Group LLC increased its holdings in shares of Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after purchasing an additional 99 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA bought a new position in shares of Becton, Dickinson and Company during the first quarter worth approximately $31,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently commented on BDX. Royal Bank Of Canada reaffirmed a "sector perform" rating and set a $211.00 target price on shares of Becton, Dickinson and Company in a report on Thursday. Wells Fargo & Company raised their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a report on Friday, August 8th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Morgan Stanley raised their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Finally, Piper Sandler reaffirmed a "neutral" rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $205.40.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the business's stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director owned 22,226 shares of the company's stock, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 1,838 shares of company stock worth $348,392 over the last quarter. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $189.20 on Friday. The firm's fifty day moving average price is $190.60 and its two-hundred day moving average price is $184.63. The stock has a market cap of $54.23 billion, a PE ratio of 34.03, a PEG ratio of 1.48 and a beta of 0.25. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The firm had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. On average, equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company's payout ratio is presently 74.82%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.